MY158712A - Therapies for preventnig or suppressing clostridium difficile infection - Google Patents

Therapies for preventnig or suppressing clostridium difficile infection

Info

Publication number
MY158712A
MY158712A MYPI2012002466A MYPI2012002466A MY158712A MY 158712 A MY158712 A MY 158712A MY PI2012002466 A MYPI2012002466 A MY PI2012002466A MY PI2012002466 A MYPI2012002466 A MY PI2012002466A MY 158712 A MY158712 A MY 158712A
Authority
MY
Malaysia
Prior art keywords
preventnig
therapies
difficile infection
clostridium difficile
antibodies
Prior art date
Application number
MYPI2012002466A
Other languages
English (en)
Inventor
Clifford Shone
April Roberts
John Landon
Original Assignee
The Sec Dep Of Health
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2010/050288 external-priority patent/WO2010094970A1/en
Application filed by The Sec Dep Of Health, Micropharm Ltd filed Critical The Sec Dep Of Health
Publication of MY158712A publication Critical patent/MY158712A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MYPI2012002466A 2009-12-04 2010-12-06 Therapies for preventnig or suppressing clostridium difficile infection MY158712A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins

Publications (1)

Publication Number Publication Date
MY158712A true MY158712A (en) 2016-11-15

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012002466A MY158712A (en) 2009-12-04 2010-12-06 Therapies for preventnig or suppressing clostridium difficile infection

Country Status (10)

Country Link
US (1) US8921529B2 (enExample)
EP (1) EP2506877B1 (enExample)
JP (1) JP5877161B2 (enExample)
CN (1) CN102740889A (enExample)
BR (1) BR112012013496A2 (enExample)
CA (1) CA2782639C (enExample)
GB (1) GB0921288D0 (enExample)
MY (1) MY158712A (enExample)
SG (1) SG181127A1 (enExample)
WO (1) WO2011067616A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ZA201401683B (en) 2013-03-08 2017-06-28 Cipla Ltd Pharmaceutical compositions for rectal administration
US20160030542A1 (en) * 2013-03-15 2016-02-04 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
US20070265187A1 (en) * 2004-04-29 2007-11-15 Slobodan Vukicevic Oral Formulations Comprising Bone Morphogenetic Proteins For Treating Metabolic Bone Diseases
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
JP5877161B2 (ja) 2016-03-02
US8921529B2 (en) 2014-12-30
BR112012013496A2 (pt) 2016-08-16
WO2011067616A1 (en) 2011-06-09
EP2506877A1 (en) 2012-10-10
CN102740889A (zh) 2012-10-17
US20130004561A1 (en) 2013-01-03
EP2506877B1 (en) 2021-08-04
SG181127A1 (en) 2012-07-30
AU2010325764A1 (en) 2012-06-07
JP2013512889A (ja) 2013-04-18
GB0921288D0 (en) 2010-01-20
CA2782639C (en) 2019-02-26
CA2782639A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
SG10201804809RA (en) Clostridium difficile antibodies
NZ705370A (en) Fcγriib-specific fc region variant
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
IN2014KN01715A (enExample)
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
NZ630542A (en) Methods of treating a tauopathy
WO2012092469A3 (en) Clostridium difficile antigens
MX2010008035A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas.
GB201201314D0 (en) Composition
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
NZ606195A (en) Methods and compositions for liver cancer therapy
GEP20146181B (en) Anti cxcr4 antibodies for treatment of hiv
MX2012011926A (es) Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
UA108636C2 (xx) Пептид
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
PL2126049T3 (pl) Przeciwciała przeciwko ludzkiemu wirusowi cytomegalii (HCMV)
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
BR112012013496A2 (pt) "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".
MX2011006803A (es) Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.